Interní Med. 2009; 11(9): 402-404

Selected updates on immunosuppressant indications

MUDr. Jan Strojil1, MUDr. Hana Ciferská, Ph.D2
1 Ústav farmakologie LF UP a FN Olomouc
2 III. interní klinika FN a LF UP Olomouc

The article presents selected updates on the use of immunosuppressants in “off-label” indications. It presents several recent studies and

updates, with focus on adalimumab in Crohn’s disease, rituximab and mycophenolate-mofetil in SLE, natalizumab in Crohn’s disease,

and also mentions the possible use of infliximab or etanercept in bronchial asthma or alcoholic hepatitis.

Keywords: imunosuprese, infliximab, adalimumab, rituximab, mykofenolát-mofetil, natalizumab.

Published: October 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Strojil J, Ciferská H. Selected updates on immunosuppressant indications. Interní Med. 2009;11(9):402-404.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. http://www.vzp.cz/cms/internet/cz/Lekari/Ciselniky/690/Hromadne-vyrabene-lecive-pripravky/Atc.xls - přistoupeno 30. 4. 2009.
    2. Hanauer SB, Sandborn WJ, et al. Human anti-tumor necrosis factor monoclonal antipody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333. Go to original source... Go to PubMed...
    3. Sandborn WJ, Hanauer SB, et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 2007; 56: 1232-1239. Go to original source... Go to PubMed...
    4. Colombel JF, Sandborn WJ, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. Go to original source... Go to PubMed...
    5. Loftus EV, Feagan BG, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008; 103(12): 3132-3141. Go to original source... Go to PubMed...
    6. Feagan BG, Panaccione R, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135(5): 1493-1499. Go to original source... Go to PubMed...
    7. Sandborn WJ, Rutgeerts P, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838. Go to original source... Go to PubMed...
    8. Oussalah A, Laclotte C, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008; 15, 28(8): 966-972. Go to original source... Go to PubMed...
    9. Dentener MA, Creutzberg EC, et al. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration. 2008; 76(3): 275-282. Go to original source... Go to PubMed...
    10. Ying S, Robinson DS, et al. TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy 1991; 21: 745-750. Go to original source... Go to PubMed...
    11. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factoralpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995; 152: 76-80. Go to original source... Go to PubMed...
    12. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol. 2008; 121(1): 5-10. Go to original source... Go to PubMed...
    13. Bozic C, Belcher G. Natalizumab in Patients with Relapsing Multiple Sclerosis: Updated Utilization and Safety Results Including TOUCH and TYGRIS. Poster, 61st Annual Meeting of the American Academy of Neurology, IV/2009.
    14. Spahr L, Giostra E, et al. Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. J Hepatol. 2004; 41(2): 229-234. Go to original source... Go to PubMed...
    15. Spahr L, Rubbia-Brandt L, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. E J Hepatol. 2002; 37(4): 448-455. Go to original source... Go to PubMed...
    16. Hommes DW, Erkelens W, et al. A double-blind, placebocontrolled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008; 42(5): 522-526. Go to original source... Go to PubMed...
    17. Autio RA, Karppinen J, et al. The effect of infliximab, a monoclonal antibody against TNF-alpha, on disc herniation resorption: a randomized controlled study. Spine. 2006; 1, 31(23): 2641-2645. Go to original source... Go to PubMed...
    18. Korhonen T, Karppinen J, et al. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine. 2005; 15, 30(24): 2724-2728. Go to original source... Go to PubMed...
    19. Burns JC, Best BM, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008; 153(6): 833-838. Go to original source... Go to PubMed...
    20. Moore AR, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis Arthritis Research & Therapy 2006; 8: R182. Go to original source... Go to PubMed...
    21. Appel GB, Contreras G, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5): 1103-1112. Go to original source... Go to PubMed...
    22. US National Institutes of Health, Clinical Trials. gov, přistoupeno 1. 5. 2009.
    23. Gürcan HM, Keskin DB, et al. A review of the current use of rituximab in autoimmune diseases. International Immunopharmacology 9, 2009: 10-25. Go to original source... Go to PubMed...
    24. Tokunaga M, Saito K, et al. Efficacy of Rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66(4): 470-475. Go to original source... Go to PubMed...
    25. Kimby E. Tolerability and safety of Rituximab (MabThera). Cancer Treat Rev 2005; 31 (6): 456-473. Go to original source... Go to PubMed...
    26. Sandborn WJ, Colombel JF, et al. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925. Go to original source... Go to PubMed...
    27. Targan S, Feagan B. Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-1683. Go to original source... Go to PubMed...
    28. US Food and Drug Administration. FDA alert: natalizumab (Tysabri), http://www.fda.gov/cder/drug/Infopage/natalizumab/default.htm; May 22, 2006.
    29. EMEA, http://www.emea.europa.eu/humandocs/PDFs/EPAR/natalizumab/H-624-RAR-en.pdf, přistoupeno 30. 4. 2009.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.